Education
About Us
Working with TipRanks
Follow Us
IBB - AI Analysis
Top Page
iShares Biotechnology ETF (IBB)
Rating:66Neutral
Price Target:
$169.00
Positive Factors
Strong Top Holdings
Several key positions, such as Alnylam Pharma and Insmed, have delivered strong year-to-date performance, boosting the ETF's returns.
Focused Sector Exposure
The ETF is heavily concentrated in the health care sector, benefiting from the growth potential of biotechnology companies.
Reasonable Expense Ratio
The ETF charges a competitive expense ratio, making it a cost-effective choice compared to actively managed funds.
Negative Factors
Over-Concentration in Health Care
With nearly all assets in the health care sector, the ETF is highly exposed to risks specific to biotechnology and pharmaceuticals.
Limited Geographic Diversification
The ETF is overwhelmingly focused on U.S. companies, offering minimal exposure to international markets.
Mixed Performance Among Holdings
While some holdings have performed well, others like Regeneron have lagged, potentially dragging down overall returns.
IBB vs. SPDR S&P 500 ETF (SPY)
AUM6.58B
RegionNorth America
Expense Ratio0.44%
Beta0.84
IssueriShares
Inception DateFeb 05, 2001
Dividend Yield0.17%
Asset ClassEquity
Index TrackedNYSE Biotechnology (TR)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,909,441
30 Day Avg. Volume1,882,587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
193.40Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering242
IBB Summary
The iShares Biotechnology ETF (IBB) is an investment fund that focuses on companies in the biotechnology sector, which is part of the broader health care industry. It tracks an index of U.S.-listed biotech companies, including well-known names like Gilead Sciences and Vertex Pharmaceuticals. These companies are involved in cutting-edge medical research, such as developing new drugs and therapies. Investors might consider IBB for potential growth, as biotechnology is a rapidly advancing field with significant contributions to health care innovation. However, new investors should be aware that the ETF’s performance can be volatile, as it depends heavily on the success of biotech research and the overall health care market.
How much will it cost me?The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to track the biotechnology industry. It’s a reasonable cost for the specialized exposure it provides.
What would affect this ETF?The iShares Biotechnology ETF (IBB) could benefit from advancements in medical research, increased demand for innovative treatments, and supportive government policies for health care innovation. However, it may face challenges from regulatory hurdles, high development costs, and potential market volatility tied to interest rate changes or broader economic conditions. Its focus on U.S.-listed biotechnology companies means it is heavily influenced by trends in the U.S. health care sector and the performance of top holdings like Gilead Sciences and Vertex Pharmaceuticals.
IBB Top 10 Holdings
The iShares Biotechnology ETF is heavily concentrated in U.S.-based biotech companies, with a strong focus on innovation in health care. Alnylam Pharmaceuticals and Insmed are rising stars, driving the fund’s performance with impressive clinical trial results and robust momentum. Meanwhile, Vertex Pharmaceuticals and Regeneron are showing mixed signals, with steady fundamentals but lagging recent performance. Gilead Sciences remains a steady anchor, benefiting from its focus on HIV and oncology treatments. Overall, the fund leans heavily into the biotech sector’s promise, but some holdings face valuation and profitability challenges that could temper gains.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | 7.54% | $497.14M | $106.97B | -12.18% | 75 Outperform | |
| Gilead Sciences | 7.41% | $488.74M | $147.04B | 34.22% | 78 Outperform | |
| Amgen | 7.17% | $472.51M | $157.08B | -7.53% | 70 Outperform | |
| Regeneron | 6.12% | $403.23M | $68.61B | -29.25% | 79 Outperform | |
| Alnylam Pharma | 5.55% | $365.54M | $63.13B | 71.09% | 60 Neutral | |
| IQVIA Holdings | 3.37% | $221.99M | $37.10B | 0.83% | 77 Outperform | |
| Argenx Se | 3.24% | $213.83M | $51.24B | 48.98% | 76 Outperform | |
| Insmed | 3.17% | $208.69M | $35.29B | 137.50% | 57 Neutral | |
| Mettler-Toledo | 2.62% | $172.42M | $28.72B | 7.06% | 69 Neutral | |
| Natera | 2.34% | $154.26M | $26.46B | 52.14% | 70 Neutral |
IBB Technical Analysis
Positive
―
Price Trends
146.37
Positive
138.80
Positive
133.84
Positive
Market Momentum
3.26
Positive
69.67
Neutral
79.76
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBB, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 153.72, equal to the 50-day MA of 146.37, and equal to the 200-day MA of 133.84, indicating a bullish trend. The MACD of 3.26 indicates Positive momentum. The RSI at 69.67 is Neutral, neither overbought nor oversold. The STOCH value of 79.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBB.
IBB Peer Comparison
Comparison Results
Performance Comparison
IBB
iShares Biotechnology ETF
157.31
17.29
12.35%
XBI
SPDR S&P BIOTECH ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents